Welcome to THAOS

Ando Y, Ueda M. Novel methods for detecting amyloidogenic proteins in transthyretin related amyloidosis. Front Biosci.
2008 May 1; 13:5548-58.

Benson MD, Yazaki M, Magy N. Laboratory assessment of transthyretin amyloidosis. Clin Chem Lab Med. 2002 Dec;40 (12):1262-5.

Bergen HR 3rd, Zeldenrust SR, Butz ML, Snow DS, Dyck PJ, Dyck PJ, Klein CJ, O'Brien JF, Thibodeau SN, Muddiman DC. Identification of transthyretin variants by sequential proteomic and genomic analysis. Clin Chem. 2004 Sep;50(9):1544-52.

Bergen HR 3rd, Zeldenrust SR, Naylor S. An on-line assay for clinical detection of amyloidogenic transthyretin variants directly from serum. Amyloid. 2003 Sep;10 (3):190-7.

Buxbaum J, Koziol J, Connors LH. Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity. Amyloid. 2008 Dec;15 (4):255-61.

Damas AM, Saraiva MJ. Review: TTR amyloidosis-structural features leading to protein aggregation and their implications on therapeutic strategies. J Struct Biol. 2000 Jun;130 (2-3):290-9.

Ferlini A, Fini S, Salvi F, Patrosso MC, Vezzoni P, Forabosco A. Molecular strategies in genetic diagnosis of transthyretin-related hereditary amyloidosis. FASEB J. 1992 Jul;6 (10):2864-6.

Gustavsson A, Jahr H, Tobiassen R, Jacobson DR, Sletten K, Westermark P. Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis. Lab Invest. 1995 Nov;73 (5):703-8.

Hazenberg BP, van Gameren II, Bijzet J, Jager PL, van Rijswijk MH. Diagnostic and therapeutic approach of systemic amyloidosis. Neth J Med. 2004 Apr;62(4):121-8.

Lewis WD. Liver transplantation: an effective treatment for familial ATTR amyloidosis. Amyloid. 2002 Sep;9 (3):201-2

Lobato L, Beirão I, Silva M, Bravo F, Silvestre F, Guimarães S, Sousa A, Noël LH, Sequeiros J. Familial ATTR amyloidosis: microalbuminuria as a predictor of symptomatic disease and clinical nephropathy. Nephrol Dial Transplant. 2003 Mar;18(3):532-8.

Murrell JR, Schoner RG, Liepnieks JJ, Rosen HN, Moses AC, Benson MD. Production and functional analysis of normal and variant recombinant human transthyretin proteins. J Biol Chem. 1992 Aug 15;267(23):16595-600.

Olsson M, Hellman U, Planté-Bordeneuve V, Jonasson J, Lång K, Suhr OB. Mitochondrial haplogroup is associated with the phenotype of familial amyloidosis with polyneuropathy in Swedish and French patients. Clin Genet. 2009 Feb;75
(2):163-8.

Saraiva MJ. Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies.
Expert Rev Mol Med. 2002 May 14;4(12):1-11.

Saraiva MJ. Transthyretin amyloidosis: a tale of weak interactions. FEBS Lett. 2001 Jun 8;498(2-3):201-3

Saraiva MJ. Transthyretin mutations in health and disease. Hum Mutat. 1995;5 (3):191-6.

Suhr OB, Herlenius G, Friman S, Ericzon BG. Liver transplantation for hereditary transthyretin amyloidosis. Liver Transpl.
2000 May;6 (3):263-76

Sekijima Y, Kelly JW, Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des. 2008;14 (30):3219-30.

Sekijima Y, Wiseman RL, Matteson J, Hammarström P, Miller SR, Sawkar AR, Balch WE, Kelly JW. The biological and chemical basis for tissue-selective amyloid disease. Cell. 2005 Apr 8;121 (1):73-85.

Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, Singleton A, Kiuru-Enari S, Paetau A, Tienari PJ, Myllykangas L. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008; 40(3):232-9.

Westermark P, Bergström J, Solomon A, Murphy C, Sletten K. Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations. Amyloid. 2003 Aug;10 Suppl 1:48-54.

Westermark P, Sletten K, Johansson B, Cornwell GG 3rd. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A. 1990 Apr;87 (7):2843-5.